Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study will prospectively collect airway, stool, and blood samples on 80 subjects with lung cancer undergoing immunotherapy. Investigators will evaluate airway/stool microbial signatures associated with local (lower airway) and systemic (blood) immune tone.They will then study whether microbiota and/or host signatures predict subjects' response by longitudinal assessment of the progression free survival. They will also repeat sampling after 8 weeks of immunotherapy to expand our mechanistic understanding of the response to treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
Locations
United States
New York
NYU Langone Health
RECRUITING
New York
Contact Information
Primary
Lira Gutierrez
Lira.Gutierrez@nyulangone.org
212-263-6181
Backup
Rosemary Schluger
Rosemary.Schluger@nyulangone.org
Time Frame
Start Date: 2021-02-09
Estimated Completion Date: 2027-02
Participants
Target number of participants: 40
Treatments
Advanced stage unresectable Non-Small Cell Lung Cancer
Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
Related Therapeutic Areas
Sponsors
Leads: NYU Langone Health
Collaborators: National Cancer Institute (NCI)